Eyewire Today http://eyewiretoday.com/ Eyewire Today en-us Wed, 16 Apr 2014 16:16:18 GMT Wed, 16 Apr 2014 16:16:18 GMT EyewireToday.com Analysis: Spinal Cord Injuries Costly, Deadly http://eyewiretoday.com/view.asp?url=20131217-analysis_spinal_cord_injuries_costly_deadly Spinal cord injury-related hospitalizations cost Americans approximately $1.69 billion in 2009, a new analysis reveals. (Spinal Cord e-pub) Length of hospital stays for SCIs were 2.5 times higher than for non-SCI patients, and average charges were fo... Tue, 17 Dec 2013 14:12:00 GMT Non-apnea Sleep Disorders Associated with Stroke Risk http://eyewiretoday.com/view.asp?url=20131217-non-apnea_sleep_disorders_associated_with_stroke_risk Patients with nonapnea sleep disorders (NSD) are at increased risk for developing ischemic stroke, compared to patients without diagnosed sleep disorder, new data show. Men and the elderly are at greatest risk, according to the analysis in Sleep Medi... Tue, 17 Dec 2013 14:00:00 GMT Preliminary Results from WED/RLS “Patient Odyssey” Survey http://eyewiretoday.com/view.asp?url=20131115-preliminary_results_from_wedrls_patient_odyssey_survey The Willis-Ekbom Disease (WED) Foundation and XenoPort released preliminary results from the Patient Odyssey survey, which reveal the challenges experienced by patients with Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED). The survey kicked off... Fri, 15 Nov 2013 16:07:00 GMT New Tysabri® Data Show Earlier Treatment and Longer-Term Use Result in Significant Reductions in MS Disease Activity http://eyewiretoday.com/view.asp?url=20131003-new_tysabri_data_show_earlier_treatment_and_longer-term_use_result_in_significant_reductions_in_ms_disease_activity Biogen Idec (NASDAQ: BIIB) today announced results from several new analyses of TYSABRI (natalizumab) data that demonstrate its effectiveness in reducing multiple sclerosis (MS) disease activity. This effect was particularly significant in people wit... Thu, 3 Oct 2013 14:39:00 GMT New Guidelines Support Gabapentin Enacarbil for RLS/WED http://eyewiretoday.com/view.asp?url=20130926-new_guidelines_support_gabapentin_enacarbil_for_rlswed The updated treatment algorithm for patients with chronic persistent restless legs syndrome/Willis-Ekbom disease (RLS/WED) includes gabapentin enacarbil, the active ingredient in HORIZANT (gabapentin enacarbil) Extended-Release Tablets, XenoPort, Inc... Thu, 26 Sep 2013 14:10:00 GMT Migraine May be Common but Overlooked in Teen Girls http://eyewiretoday.com/view.asp?url=20130628-migraine_may_be_common_but_overlooked_in_teen_girls Up to 18 percent of teenage girls may have definite migraine, based on the International Headache Classification and 25 percent have probably migraine, a recent study published in the Journal of Pediatric Neurology suggests. Another 45 percent have n... Fri, 28 Jun 2013 05:26:00 GMT Ketogenic Diet May Aid Autism http://eyewiretoday.com/view.asp?url=20130628-ketogenic_diet_may_aid_autism A ketogenic diet may independently reduce behaviors associated with autism spectrum disorders, new research on mice suggests. Research has suggested that the 100-year old therapeutic diet may benefit neurological conditions besides epilepsy, includin... Fri, 28 Jun 2013 05:21:00 GMT ALS Research Make Promising Gene Discovery http://eyewiretoday.com/view.asp?url=20130628-als_research_make_promising_gene_discovery Researchers from Northwestern University's School of Medicine studying amyotrophic lateral sclerosis (ALS) have for the first time identified a gene both in motor neurons in the brain and spinal cord affected by ALS. The finding could lead the way to... Fri, 28 Jun 2013 05:14:00 GMT Glioma induced immunosuppression increases progression-free survival in a trial of immunotherapy for glioblastoma http://eyewiretoday.com/view.asp?url=20130503-glioma_induced_immunosuppression_shortens_progression-free_survival_in_a_trial_of_immunotherapy_for_glioblastoma Preliminary data from a Phase II clinical trial showed that newly diagnosed glioblastoma multiforme (GBM) patients treated with Prophage G-100 (Heat Shock Protein-Peptide Complex-96, HSPPC-96) vaccine plus the standard of care showed a 146 percent in... Fri, 3 May 2013 16:00:00 GMT Data: High Satisfaction Among PD Patients with GI Effects Switched to Neupro http://eyewiretoday.com/view.asp?url=20130320-data_released_on_switching_pd_patients_with_pre-existing_gastrointestinal_symptoms_from_oral_pd_medications_to_neupro New data from a non-interventional, observational study found that when Parkinsons disease (PD) patients were switched from an oral PD medication to Neupro (Rotigotine Transdermal System), they reported improvements in pre-existing gastrointestinal (... Wed, 20 Mar 2013 18:30:00 GMT Research uncovers a potential link between Parkinson’s and visual problems http://eyewiretoday.com/view.asp?url=20130219-research_uncovers_a_potential_link_between_parkinsons_and_visual_problems The most common genetic cause of Parkinsons is not only responsible for the conditions distinctive movement problems but may also affect vision, according to new research by scientists at the University of York. Tue, 19 Feb 2013 17:29:00 GMT New Study Focuses on Veterans with Epilepsy http://eyewiretoday.com/view.asp?url=20130219-new_study_focuses_on_veterans_with_epilepsy The Department of Veterans Affairs' Epilepsy Centers of Excellence (ECoE), biopharmaceutical company UCB, and health data-sharing website Patients Like Meare partnering on a new study they hope will further understanding of what factors improve healt... Tue, 19 Feb 2013 16:43:00 GMT AES Data Support Long-term Efficacy, Safety of Lacosamide http://eyewiretoday.com/view.asp?url=20130219-aes_data_support_long-term_efficacy_safety_of_lacosamide Research evaluating safety and efficacy of Vimpat (lacosamide) C-V in adults with partial-onset seizures (POS) and in other special populations was presented at the 66th Annual Meeting of the American Epilepsy Society . -- Included in presentations ... Tue, 19 Feb 2013 16:38:00 GMT